ZOLAR is a first-in-human, proof-of-concept and biodistribution trial that uses positron emission tomography (PET) to evaluate olaratumab, a monoclonal antibody, as a therapeutic radiopharmaceutical ...

CNS Pharmaceuticals (NASDAQ: CNSP) a biopharmaceutical company targeting brain and CNS cancers, reported a full-year 2024 net loss of $14.9 million, ...

The addition of nivolumab to neoadjuvant chemotherapy significantly increased pathologic complete response among certain patients with breast cancer, according to findings published in Nature Medicine ...

近日，北京中医药大学东直门医院王勇教授和广州中医药大学王伟教授团队在Medicine Plus上发表综述文章“Anthracycline-induced cardiotoxicity: emerging mechanisms and ...

CNS Pharmaceuticals (NASDAQ: CNSP) announced results from its Phase 2 clinical trial evaluating Berubicin for recurrent or progressive Glioblastoma ...

CNS Pharmaceuticals (CNSP) announced the primary analysis of its clinical trial evaluating Berubicin, the first anthracycline demonstrated to ...

Berubicin showed clinically relevant outcomes comparable to Lomustine across multiple endpoints, but not a statistically significant difference in overall survival, the primary endpoint.The safety pro ...

Phase III IMvoke010 trial found that maintenance treatment with Tecentriq (atezolizumab) did not significantly improve ...

The field of cardio-oncology has expanded over the past 2 decades to address the ever-increasing issues related to cardiovascular disease in patients with cancer and survivors. There is increasing ...

Moleculin's novel drug candidate is being positioned to become the first ever non-cardiotoxic anthracycline to be approved and is currently being developed for the treatment of acute myeloid ...

And the benefits were found to be particularly promising for breast cancer patients receiving a common chemotherapy type called anthracycline chemotherapy, which can affect heart health.